Publication | Closed Access

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

Hematological MalignancySystems BiologyOncologyCbl MutationsEngineeringMedicineMixed-phenotype Acute LeukemiaHematologyCancer GeneticsRadiation OncologyMolecular DiagnosticsCell BiologyCancer ResearchRelative Mutant LevelMyeloid Neoplasia